Dr. Bansilal was an Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai when he decided to seek out an alternative pathway to make an impact on patients’ lives.
This week, Dr. Ankur Kalra’s guest is Dr. Sameer Bansilal, Executive Director of U.S Medical Affairs of Cardiovascular and Renal at Bayer Pharmaceutical.
After years with the TIMI Study Group, Sameer decided to leave academic medicine to join the pharmaceutical industry. He was not alone with this career move; Dr. Jessica Mega had just joined Google Life Sciences and Dr. Laura Mauri became the Vice President of Medtronic. The image of being a physician at pharma was going through a change. In this informative and honest conversation, Sameer shares his personal journey and the transformation required in his new job. Ankur and Sameer talk about expanding our views and our pilgrimage as readers. Ankur asks Sameer about the positive and negative aspects of his current job. Sameer addresses some of the preconceptions related to physicians working for the industry and shares his advice for early and mid-career cardiologists who are considering this option.
Questions and comments can be sent to “podcast@radcliffe-group.com” and may be answered by Ankur in the next episode.
Brought to you by Edwards: www.edwardstavr.com
In this practical and insightful episode, Dr Kalra asks what does diversity, equity, inclusion and belonging mean to the editorial board of JCF and what were the steps taken to put these principles into practice.
They talk about AI assisted consultation, learning pathways incorporating simulators for early career practitioners and the Flying Eye Hospital. Dr Cherwek shares his experiences about working with local teams globally and the work that goes into setting up trials across the world.
Dr Ankur Kalra’s guests this week are Dr Martha Gulati, internationally recognized cardiologist specializing in Women and Heart Disease, Heart Disease Prevention and Dr Devesh Rai, first year cardiology fellow at Rochester General Hospital.
In this episode, Ankur and Danielle speak about the evidence in favour of a whole-food plant-based diet to improve cardiovascular health, the ACC prevention guidelines, how to talk to patients about positive dietary change, the issue of lack of nutrition training in cardiovascular fellowships and what Danielle’s diet looks like as a busy whole-food plant-based cardiology fellow. On her own podcast ‘Nutrition Rounds’ Danielle has discussions about evidence-based plant-based nutrition with physicians who are leading experts in nutrition and health.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
In this brilliant conversation, Ankur, Emmanouil and Michael unravel the potential advantages, challenges and practical realities of using drug-coated balloons in SVD, and the findings of the latest randomised controlled trials studying this area.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology. [Disclaimer: The use of drug-coated balloons in coronay intervention is still off-label; it has not been approved by the FDA.]
Dawn is an associate editor of the journal Circulation: Cardiovascular Interventions and is widely known for her research program on PCI and peripheral arterial disease (PAD). Ankur and J. Dawn discuss multiple trials/studies that were published in 2018, including ORBITA, PIONEER-II and ABSORB. J. Dawn also shares her thoughts on the latest stent technologies.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
They discuss the importance of preventative medicine, their experience of reducing hypertension with non-pharmaceutical and pharmaceutical methods, and the significance of the integrated “team approach” when treating comorbid conditions such as hypertension. Athena also shares her thoughts on cardiologists’ responsibility to shape their patients’ lifestyle choices.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Chest pain is one of the most common reasons for an emergency room visit in the US, with almost 6 million ER visits annually, yet there is no consensus on how to compare the results from various hscTn assays. Tune in to hear Santiago outline the advantages and limitations of using hscTn as a standard biomarket to evaluate patients with suspected ACS in the ER.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.